HUC3-637 for primary open-angle glaucoma and ocular hypertension
A Multicenter, Randomized, Single-blind, Active Controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
This study tests whether HUC3-637 is safe and can lower eye pressure in adults with primary open-angle glaucoma or ocular hypertension.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 206 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | Huons Co., Ltd. Industry-sponsored |
| Locations | 1 site (Seoul) |
| Trial ID | NCT07335211 on ClinicalTrials.gov |
What this trial studies
This is a multicenter, randomized, single-blind, active-controlled phase III trial comparing HUC3-637 and HUC3-637-R in adults with primary open-angle glaucoma or ocular hypertension. Eligible participants are age 19 or older, have a diagnosis of POAG or ocular hypertension, and must provide written informed consent; patients with angle-closure, congenital, or secondary glaucoma are excluded. The trial will monitor efficacy and safety outcomes over the treatment period, with scheduled clinic visits at participating centers (detailed endpoints and visit schedule are not provided in the registry entry). The lead sponsor is Huons Co., Ltd., and the listed site for enrollment is Kangbuk Samsung Hospital in Seoul.
Who should consider this trial
Good fit: Adults aged 19 or older with a diagnosis of primary open-angle glaucoma or ocular hypertension who can give informed consent are the intended candidates.
Not a fit: People with acute or chronic angle-closure glaucoma, congenital glaucoma, secondary open-angle glaucoma, or those under 19 years old are unlikely to benefit from this intervention.
Why it matters
Potential benefit: If successful, HUC3-637 could provide an additional option to lower intraocular pressure with a favorable safety profile for people with POAG or ocular hypertension.
How similar studies have performed: While established drug classes for lowering intraocular pressure have proven effective, HUC3-637 appears to be a novel agent with limited published phase III data to date.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 19 years and older * Participants diagnosed with POAG or OH * Have fully explained and understood the study and have voluntarily given written informed consent. Exclusion Criteria: * Acute or chronic angle-closure glaucoma * Congenital glaucoma, secondary glaucoma (open-angle glaucoma)
Where this trial is running
Seoul
- Kangbuk Samsung Hospital — Seoul, South Korea (Recruiting)
Study contacts
- Study coordinator: Rang Lee
- Email: rlee@huons.com
- Phone: 07074926091
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.